Martina M.D. Flammer Sells 33,055 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 33,055 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the sale, the insider now owns 138,053 shares in the company, valued at $11,168,487.70. The trade was a 19.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, January 14th, Martina M.D. Flammer sold 1,384 shares of Insmed stock. The shares were sold at an average price of $68.72, for a total value of $95,108.48.
• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Trading Down 1.0 %

Shares of INSM stock traded down $0.83 during trading hours on Friday, reaching $79.95. 1,690,520 shares of the stock traded hands, compared to its average volume of 1,955,787. The business has a fifty day moving average price of $72.79 and a 200 day moving average price of $73.10. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $82.04. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $14.30 billion, a PE ratio of -14.41 and a beta of 1.11.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Truist Financial restated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday. Morgan Stanley increased their target price on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. Finally, Guggenheim increased their price objective on shares of Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Insmed has an average rating of “Moderate Buy” and an average price target of $85.00.

Institutional Trading of Insmed

A number of hedge funds have recently modified their holdings of INSM. Steward Partners Investment Advisory LLC raised its position in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares during the period. V Square Quantitative Management LLC purchased a new stake in shares of Insmed in the third quarter worth approximately $30,000. GAMMA Investing LLC boosted its holdings in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares during the period. Spire Wealth Management purchased a new position in Insmed during the fourth quarter valued at approximately $47,000. Finally, Exchange Traded Concepts LLC increased its stake in Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 627 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.